NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT02897765 2021-02-25A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerBioNTech SEPhase 1 Completed34 enrolled
NCT00948961 2016-06-27A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1Celldex TherapeuticsPhase 1/2 Completed70 enrolled